DE69020582T2 - Verwendung von Melatonin zur Behandlung des prämenstruellen Syndroms. - Google Patents

Verwendung von Melatonin zur Behandlung des prämenstruellen Syndroms.

Info

Publication number
DE69020582T2
DE69020582T2 DE69020582T DE69020582T DE69020582T2 DE 69020582 T2 DE69020582 T2 DE 69020582T2 DE 69020582 T DE69020582 T DE 69020582T DE 69020582 T DE69020582 T DE 69020582T DE 69020582 T2 DE69020582 T2 DE 69020582T2
Authority
DE
Germany
Prior art keywords
melatonin
premenstrual syndrome
treat premenstrual
treat
pms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69020582T
Other languages
English (en)
Other versions
DE69020582D1 (de
Inventor
Michael Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Medical Research Ltd
Original Assignee
Applied Medical Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27154756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69020582(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Medical Research Ltd filed Critical Applied Medical Research Ltd
Application granted granted Critical
Publication of DE69020582D1 publication Critical patent/DE69020582D1/de
Publication of DE69020582T2 publication Critical patent/DE69020582T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
DE69020582T 1989-01-17 1990-02-09 Verwendung von Melatonin zur Behandlung des prämenstruellen Syndroms. Expired - Fee Related DE69020582T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/297,328 US4945103A (en) 1989-01-17 1989-01-17 Method of treating pre-menstrual syndrome
AU51928/90A AU642864B2 (en) 1989-01-17 1990-02-09 Method of treating pre-menstrual syndrome
PCT/US1990/000154 WO1991012007A1 (en) 1989-01-17 1990-02-09 Method of treating pre-menstrual syndrome
CA002075904A CA2075904C (en) 1989-01-17 1990-02-09 Method of treating pre-menstrual syndrome

Publications (2)

Publication Number Publication Date
DE69020582D1 DE69020582D1 (de) 1995-08-03
DE69020582T2 true DE69020582T2 (de) 1996-01-04

Family

ID=27154756

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69020582T Expired - Fee Related DE69020582T2 (de) 1989-01-17 1990-02-09 Verwendung von Melatonin zur Behandlung des prämenstruellen Syndroms.

Country Status (11)

Country Link
US (1) US4945103A (de)
EP (1) EP0514373B1 (de)
KR (1) KR0171408B1 (de)
AT (1) ATE124260T1 (de)
AU (1) AU642864B2 (de)
CA (1) CA2075904C (de)
DE (1) DE69020582T2 (de)
EG (1) EG19304A (de)
ES (1) ES2074565T3 (de)
IL (1) IL93053A (de)
WO (1) WO1991012007A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
ATE181670T1 (de) * 1991-05-09 1999-07-15 Neurim Pharma 1991 Melatonin enthaltende arzneimittel
EP0608362A1 (de) * 1991-10-18 1994-08-03 Alza Corporation Vorrichtung zur transdermalen verabreichung von melatomin
EP0565296B1 (de) * 1992-04-07 1996-08-07 Neurim Pharmaceuticals (1991) Limited Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie
US5385736A (en) * 1993-07-12 1995-01-31 Minnesota Mining And Manufacturing Company Transdermal melatonin delivery system
AU7550994A (en) * 1993-07-26 1995-02-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
CA2255838A1 (en) * 1996-05-20 1997-11-27 Richard C. Fuisz Melatonin in combination with analgesics
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6133453A (en) * 1998-05-15 2000-10-17 Pharm-Eco Laboratories, Inc. Method for making substituted indoles
US20040131579A1 (en) * 1998-09-10 2004-07-08 Avon Products, Inc. Method and compositions for reducing dermatological aging and for reducing bruising
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
DE19957710A1 (de) * 1999-11-30 2001-05-31 Asat Ag Applied Science & Tech Verwendung von Melatonin zur Behandlung der androgenetischen Alopezie
US20020119191A1 (en) * 2000-04-24 2002-08-29 Hitoo Nishino Pharmaceutical or food composition for treatment or prevention of brain edema
JP2005513080A (ja) 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
WO2004060322A2 (en) 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
WO2005039546A2 (en) 2003-10-03 2005-05-06 Veijlen N.V. Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
DK1667678T3 (da) 2003-10-03 2009-08-24 Veijlen N V Dyrefodersammensætning
KR100835183B1 (ko) * 2006-08-30 2008-06-04 엘지전자 주식회사 냉장고
KR100776294B1 (ko) * 2006-08-30 2007-11-16 엘지전자 주식회사 냉장고
EP2068695A2 (de) * 2006-09-13 2009-06-17 Koninklijke Philips Electronics N.V. Vorrichtung zur automatischen anpassung einer melatonin-dosis und/oder einer melatonin-verabreichung
MX2009010878A (es) * 2007-04-11 2010-03-26 John A Mccarty Pastilla de melatonina y metodos de preparacion y uso.
UY33103A (es) 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
KR102262306B1 (ko) 2013-07-04 2021-06-09 (주)아모레퍼시픽 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물
KR102192573B1 (ko) 2020-08-12 2020-12-18 문종진 생리통 및 피부 트러블의 예방 및 개선용 조성물
CN113876689A (zh) * 2021-11-01 2022-01-04 冷静 一种改进型褪黑素的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2967049D1 (en) * 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US4687763A (en) * 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
US4746674A (en) * 1985-08-27 1988-05-24 Cellena (Cell Engineering) Ag Melatonin compositions and uses thereof
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
NZ215767A (en) * 1986-04-09 1989-10-27 Nz Government Stimulating cashmere fibre growth on cashmere-producing goats by administration of melatonin
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
EP0311651A1 (de) * 1987-04-01 1989-04-19 Cellena (Cell Engeneering) A.G. Melatonin-derivate gegen psychogenen stress und akute angstzustände und immunstimulierende medikamente

Also Published As

Publication number Publication date
IL93053A (en) 1994-02-27
EP0514373B1 (de) 1995-06-28
CA2075904A1 (en) 1991-08-10
AU642864B2 (en) 1993-11-04
AU5192890A (en) 1991-09-03
US4945103A (en) 1990-07-31
EP0514373A1 (de) 1992-11-25
EP0514373A4 (en) 1993-03-17
ES2074565T3 (es) 1995-09-16
KR0171408B1 (ko) 1999-02-01
EG19304A (en) 1994-11-30
KR920700649A (ko) 1992-08-10
DE69020582D1 (de) 1995-08-03
WO1991012007A1 (en) 1991-08-22
CA2075904C (en) 2004-07-20
ATE124260T1 (de) 1995-07-15

Similar Documents

Publication Publication Date Title
ATE124260T1 (de) Verwendung von melatonin zur behandlung des prämenstruellen syndroms.
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ATE71843T1 (de) Behandlung des atemunwohlseinsyndroms bei erwachsenen.
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69201128T2 (de) Behandlung von neoplastischen krankenheiten mit interleukin-10.
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE3883606D1 (de) Verwendung von Fluoxetin zur Behandlung des Diabetes.
DE69004189T2 (de) Anordnungen zur behandlung menschlichen oder tierischen abfalls mittels mikrowellen.
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
DE58907851D1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE69313261D1 (de) Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
EA199800859A1 (ru) Способ лечения при ядовитых укусах и ужалениях
DE68909750T2 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
DE59009724D1 (de) Verwendung von 7-oh-1,2-benzopyron zur herstellung eines arzneimittels zur behandlung von malignen tumoren beim menschen.
ATE96486T1 (de) Anordnungen zur behandlung menschlichen oder tierischen abfalls mittels mikrowellen.
DE69118847D1 (de) Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus
SE9000658D0 (sv) Mittel zur behandlung der schlaf-apnoe
ATE95414T1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee